Sanofi Selects Recursion Immunology Drug Candidate for Development

By Public Technologies
  • Sanofi has optioned the first development candidate from its research collaboration with Recursion, adding it to its development pipeline.
  • The potential first-in-class oral small molecule, developed using AI-enabled design, targets a challenging pair of targets implicated in inflammatory disease.
  • Phase 1 trials are expected in 2027, with Sanofi funding and leading further development and commercialization.
  • The option triggered a $10 million milestone payment, bringing total upfront and milestone payments under the collaboration to $144 million.
  • Recursion remains eligible for more than $300 million in additional program milestones, with average low-double-digit royalties on net sales if successfully commercialized.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150845PRIMZONEFULLFEED9846526) on October 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.